NO20005186D0 - Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor - Google Patents

Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor

Info

Publication number
NO20005186D0
NO20005186D0 NO20005186A NO20005186A NO20005186D0 NO 20005186 D0 NO20005186 D0 NO 20005186D0 NO 20005186 A NO20005186 A NO 20005186A NO 20005186 A NO20005186 A NO 20005186A NO 20005186 D0 NO20005186 D0 NO 20005186D0
Authority
NO
Norway
Prior art keywords
enhancement
administration
immune responses
mediated immune
protein mediated
Prior art date
Application number
NO20005186A
Other languages
English (en)
Other versions
NO20005186L (no
Inventor
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20005186D0 publication Critical patent/NO20005186D0/no
Publication of NO20005186L publication Critical patent/NO20005186L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20005186A 1998-04-17 2000-10-16 Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor NO20005186L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216698P 1998-04-17 1998-04-17
PCT/US1999/008376 WO1999053958A2 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Publications (2)

Publication Number Publication Date
NO20005186D0 true NO20005186D0 (no) 2000-10-16
NO20005186L NO20005186L (no) 2000-12-14

Family

ID=22169464

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005186A NO20005186L (no) 1998-04-17 2000-10-16 Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor

Country Status (16)

Country Link
US (1) US20040033210A1 (no)
EP (1) EP1071469A2 (no)
JP (1) JP2002512204A (no)
CN (1) CN1305387A (no)
AU (1) AU758851B2 (no)
BR (1) BR9909677A (no)
CA (1) CA2328081A1 (no)
CZ (1) CZ20003817A3 (no)
HK (1) HK1038881A1 (no)
HU (1) HUP0101343A3 (no)
MX (1) MXPA00010151A (no)
NO (1) NO20005186L (no)
PL (1) PL343486A1 (no)
RU (1) RU2217168C2 (no)
WO (1) WO1999053958A2 (no)
ZA (1) ZA200005477B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
DE69942207D1 (de) * 1998-08-25 2010-05-12 Merck Patent Gmbh Expression und export von angiostatin und endostatin als immunofusins
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6227400A (en) * 1999-07-26 2001-02-13 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
SK982003A3 (en) * 2000-06-29 2004-05-04 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7148321B2 (en) * 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ES2361664T3 (es) * 2001-05-03 2011-06-21 Merck Patent Gmbh Anticuerpo recombinante para tumor específico y su utilización.
AU2002357784B2 (en) * 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
JP4723811B2 (ja) * 2002-03-15 2011-07-13 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 始原肝幹細胞および近位肝幹細胞
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AU2004309050B2 (en) 2003-12-30 2010-10-14 Merck Patent Gmbh IL-7 fusion proteins
CN1902222A (zh) * 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－***融合蛋白质
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
DE602005016773D1 (de) * 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005313492B2 (en) * 2004-12-09 2011-12-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CN101351475B (zh) * 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
AU3588097A (en) * 1996-07-02 1998-01-21 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
EP1071469A2 (en) 2001-01-31
JP2002512204A (ja) 2002-04-23
HUP0101343A2 (hu) 2001-08-28
ZA200005477B (en) 2001-11-20
MXPA00010151A (es) 2002-08-06
US20040033210A1 (en) 2004-02-19
PL343486A1 (en) 2001-08-27
RU2217168C2 (ru) 2003-11-27
CA2328081A1 (en) 1999-10-28
WO1999053958A2 (en) 1999-10-28
AU758851B2 (en) 2003-04-03
CN1305387A (zh) 2001-07-25
NO20005186L (no) 2000-12-14
HUP0101343A3 (en) 2003-10-28
HK1038881A1 (zh) 2002-04-04
AU3566499A (en) 1999-11-08
WO1999053958A3 (en) 1999-12-02
CZ20003817A3 (cs) 2002-08-14
BR9909677A (pt) 2000-12-19

Similar Documents

Publication Publication Date Title
NO20005186D0 (no) Forbedring av antistoff-cytokinfusjonsprotein medierte immunresponser ved ko-administrasjon med prostaglandin inhibitor
HUP0101352A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
NO20035426D0 (no) Fremgangsmåte ved administrering av anti-TNF-D-antistoff
DE60127894D1 (de) Verminderung der Rissneigung bei Flanschverbindungen
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
IL218666A (en) Increase antibody-mediated immune responses
FI931198A0 (fi) Biospesifinen multiparametrinen määritysmenetelmä
NO20023788L (no) Antistoff som binder humant interleukin-18 samt fremgangsmater ved fremstilling og anvendelse derav
BR0207314B1 (pt) piscina de onda e mÉtodo de criar méltiplas formaÇÕes de onda.
DE69600784D1 (de) Proteinkinase-C-Inhibitor
PL374221A1 (en) Antibody inhibitors of gdf-8 and uses thereof
DK0739214T3 (da) Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
NO20001648D0 (no) FremgangsmÕter og mellomprodukter for fremstilling av anti- cancer forbindelser
AU2002316137A1 (en) Method of determining protein interaction inhibitors
DK124588D0 (da) Doseringsformer med forsinket frigoerelse
DK38293D0 (da) Fremstilling af proteiner
DE69530078D1 (de) Antigen/antikörper spezifitätsaustauscher
MXPA03006817A (es) Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
CY2005003I2 (el) Mεθοδοι και ενδιαμεσα χρησιμα για κατασκευη αντιφολικων
DK1412486T3 (da) Fremgangsmåde til virusformering
DK0912612T3 (da) Forenklet fremstilling af bispecifikke antistoffragmenter
ITMI20022518A1 (it) Dispositivo e procedimento per minimizzare ritardo di
DE69709159D1 (de) Kreuz-dimierisierung von olefinen
ITMI941499A0 (it) Determinazione e isolamento di taxolo e 10-desacetil-bacatina iii e analoghi attraverso anticorpi
AU2002248309A1 (en) Inhibitor of apoptosis proteins and nucleic acids and methods for making and using them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application